How Much Nicotinamide Riboside Should You Give a 70-lb Dog?

By Laura Mancuso, VMD, DACVO

✓ Medically reviewed by Laura Mancuso, VMD, DACVO — August 25, 2026 For general education — not a substitute for veterinary care.

Longevity & NAD+ · August 28, 2026 · 5 min read

How much nicotinamide riboside should you give a 70-lb dog? There is no approved dose — only reasoned estimates.

A Labrador mix named Otis used to meet his owner at the door every evening, tail going before the key was even in the lock. By eleven years old, he was still there — just slower, and sometimes not there at all until the second time she called his name. His owner asked me a version of the same question I hear at least once a week from owners of large, aging dogs: if a nicotinamide riboside chew helps, how many should a 70-lb dog actually get? It sounds like a simple math problem. It is not, and I want to explain why before I give you a number.

Why “How Much” Doesn’t Have a Clean, Regulated Answer

There is no FDA-approved or AAFCO-established dose of nicotinamide riboside (NR) for dogs of any weight. Unlike a prescription drug, where dosing is set by pharmacokinetic trials in the target species, NR supplements for dogs are formulated per-chew, not per-kilogram, and owners are left to extrapolate. The NIH Office of Dietary Supplements’ human fact sheet on niacin-related compounds notes that clinical trials in people have not reported flushing or significant differences in adverse events between nicotinamide riboside and placebo groups — reassuring for tolerability, but that safety data was generated in adult humans, not in dogs, and it says nothing about the dose a 70-lb dog needs to see a cellular effect (NIH Office of Dietary Supplements). Most consumer NR chews on the market are dosed per serving rather than per pound, which means the practical question for a 70-lb dog is less “what’s the mg/kg” and more “how many servings get me into a defensible range.”

What NAD+ Precursors Are Actually Doing at the Cellular Level

NR is a precursor molecule — the body converts it into nicotinamide adenine dinucleotide (NAD+), a coenzyme every cell needs for energy metabolism and DNA repair. NAD+ levels decline with age across species, which is the biological rationale for supplementing a precursor rather than NAD+ itself, since NAD+ is poorly absorbed orally. Framed narrowly, a chew delivering nicotinamide riboside functions as a NAD+ precursor that supports normal cellular function — that is structure/function language, not a treatment claim, and it is the honest ceiling of what the ingredient does. One product fact sheet in the category lists 120 mg of nicotinamide riboside per two-chew serving as its formulated dose for dogs; I cite that only as an example of how manufacturers are currently dosing the ingredient, not as a validated per-pound target.

Working Out a Reasonable Range for a 70-lb Dog

Because no per-kilogram canine dose has been established, I tell owners to anchor on the manufacturer’s labeled serving for their dog’s weight tier rather than trying to back-calculate from a human dose — human trials used gram-scale ranges that do not translate cleanly to a 70-lb animal with a different metabolic rate. If a label’s serving is built around a mid-size dog and your dog is at the top of the large-breed range, following the label’s own weight-tier guidance is more defensible than doubling a serving on your own arithmetic. I am also explicit with owners about what this range is not: it is not a dose validated by a canine pharmacokinetic study, because none has been published that I can point to.

In my practice, I’ve watched owners of large senior dogs get stuck on exactly this arithmetic — a 72-lb shepherd mix named Duke, thirteen years old, whose owner first noticed he’d stopped taking the two porch steps in one stride sometime that January, choosing instead to pause and gather himself. She’d read that NR chews were dosed per serving, not per pound, and she wasn’t sure whether a dog Duke’s size needed one chew or two. We talked through it in the exam room on a Tuesday afternoon, her weighing the cost of doubling the serving against her uncertainty that it would do anything measurable. I told her what I’m telling you here: match the label’s weight tier, don’t improvise a multiplier, and treat any change in his stair tolerance over the following months as one dog’s experience, not proof of anything at the population level.

The Antioxidants Riding Alongside NR: Quercetin and Resveratrol

NR rarely appears alone in longevity chews; quercetin and resveratrol are common co-ingredients, and it’s worth being precise about what each has and hasn’t shown. Quercetin is a flavonoid with antioxidant properties studied for immune and cellular support, and one in-vitro investigation found that quercetin formulations, along with NAC and ascorbic acid, did not affect feeding behavior in the model organism tested at the concentrations used — a narrow finding about tolerability in a lab model, not a canine efficacy result (Pharmaceuticals (MDPI)). Resveratrol’s evidence is similarly early-stage and dose-dependent: one phytomedicine study found that embryonic exposure to a specific resveratrol-related compound accelerated developmental timing but shortened adult lifespan in the model tested, which is exactly the kind of dose-and-context-dependent result that should keep anyone cautious about extrapolating a “more is better” assumption to a chew formulated with 40 mg of resveratrol per serving (Phytomedicine). Neither study was conducted in dogs, and I say that every time, because the gap between an in-vitro finding and a clinical recommendation is where overclaiming happens.

What I Tell Owners Weighing Cost Against Certainty

The strongest counterargument to recommending NR chews at all is straightforward: independently published, peer-reviewed canine dosing and outcome data for NR specifically is thin. The most rigorous public evidence in the broader NAD+-and-senolytic category comes from a different formulation entirely — a two-part NAD+ booster and senolytic system studied in a randomized, double-blind trial at a veterinary college, where dogs in the full-dose group showed improved or stable cognition on an owner-reported scale significantly more often than dogs on placebo (SkeptVet). That trial is genuinely a higher evidentiary bar than most NR-alone products can currently point to, and I don’t pretend otherwise — it is one reason our comparison of nicotinamide riboside against NMN treats published-trial status as a real differentiator between products, not a marketing footnote. Where I still land, for a 70-lb dog with age-appropriate stiffness or slowing but no diagnosed cognitive decline, is that a labeled, weight-tier-appropriate serving of an NR chew is a low-risk, narrowly-supported structure/function choice — not a treatment, and not a substitute for working through a broader senior dog vitamin checklist with your own vet first.

I’ve had this same conversation enough times that I no longer promise a specific outcome — only a specific, bounded rationale for the dose. That’s the part I can stand behind.

Where This Leaves You

Start by checking the product’s own weight-tier guidance rather than calculating a per-pound dose yourself; no such canine dose has been established in the literature. Keep expectations narrow — NR supports normal cellular NAD+ turnover, it does not treat a diagnosed disease. If your dog has diagnosed cognitive changes rather than general slowing, read what the evidence actually supports for canine cognitive dysfunction supplements and ask your vet whether a published-trial NAD+ formula changes the calculus for your dog specifically. And bring the label to your next visit — that’s the one step that turns a guess into a plan.